Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

7.7%

2 terminated/withdrawn out of 26 trials

Success Rate

90.9%

+4.4% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

35%

7 of 20 completed trials have results

Key Signals

1 recruiting7 with results

Enrollment Performance

Analytics

Phase 1

15(57.7%)

Phase 2

11(42.3%)

26Total

Phase 1(15)

Phase 2(11)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials

NCT07033026Phase 2Recruiting

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Role: lead

NCT02443116Phase 2Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Role: lead

NCT03912532Phase 2Completed

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

Role: lead

NCT04465955Phase 2Completed

A Study of NGM621 in Participants With Geographic Atrophy

Role: lead

NCT02704364Phase 2Completed

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Role: lead

NCT04068896Phase 1Completed

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Role: lead

NCT06654726Phase 2Withdrawn

A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.

Role: lead

NCT04210245Phase 2Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Role: lead

NCT05215574Phase 1Active Not Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Role: lead

NCT04913337Phase 1Active Not Recruiting

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Role: lead

NCT05311618Phase 1Active Not Recruiting

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Role: lead

NCT05130047Phase 2Completed

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Role: collaborator

NCT04582318Phase 1Terminated

A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19

Role: lead

NCT04828265Phase 1Completed

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Role: lead

NCT04823702Phase 1Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Role: lead

NCT04187339Phase 1Completed

Study of NGM395 in Adult Participants

Role: lead

NCT04014777Phase 1Completed

Study of NGM621 in Participants With Geographic Atrophy